Bioxyne’s Dr Watson brand extends its Amazon footprint into US and Japan

Bioxyne has positioned itself to become a significant player in the biggest supplement and nootropics market in the world with its first sales for its Dr Watson brand on Amazon in the US along with Germany, France, Japan and the UK.

Healthcare company Bioxyne (ASX:BXN) has announced its trademarked Dr Watson brand mushroom nootropics are now selling on Amazon in the US, Japan, and EU markets.

CEO Sam Watson said the mushroom nootropics are formulated to enhance cognitive function, focus, memory, as well as supporting energy levels and hormone balance.

“These nootropics are a hot topic in the health and wellness industry with the US leading the way and the EU markets about to take off. Global sales of Nootropics are growing at ~15% CAGR and sales have already surpassed ~US$11bn” he said.

Watson said medicinal mushroom extracts, which are food supplements (not psylocibin) such as Lion’s Mane, Reishi, Cordyceps, Shiitake – are fast becoming the most popular replacement for coffee and other cognitive enhancers.

“We combine these mushrooms with vitamins and minerals in our proprietary formulations,” he said.

“We are now positioned to become a significant player in the biggest supplement and nootropics market in the world on the biggest Ecommerce platform.”

Dr Watson is part of Breathe Life Sciences (BLS), recently acquired by BXN, which is focused on new-pharmacopoeia alternative medicines.

These include medicinal cannabis, MDMA, Psilocybin, and “pre-pharmaceutical” consumer healthcare products such as mushrooms, nootropics, and novel food supplements (including CBD in the UK and EU) sold to businesses and direct to consumer.

BLS is also a leading supplier of cannabis-derived raw materials and active pharmaceutical ingredients (APIs) globally.

Amazon sales to deliver >80% GM with massive annual growth potential.

Dr Watson products are also being sold now on Amazon in Japan, where the company was one of the first to import CBD and currently supplies raw materials to a significant portion of the market.

“We also have a fully accredited lab for manufacturing food and vape products with CBD in Japan,” Watson said.

Watson said Japan is a market where quality and luxury succeed, and where customers pay much more for better quality and service.

“It’s a wealthy country and the highest margin part of the business,” he said.

“We forecast Amazon sales to deliver a greater than 80% GM (gross margin) with massive growth potential.”

Growing list of countries with Amazon presence

The Dr Watson brand is now present on the largest e-commerce platform in the world in the UK, Germany, France, US and Japan, USA.

Amazon is the leading retailer of health supplements in the US, accounting for AU$15Bn per year in purchases.

“There has been a huge push over the last 6-12 months for BLS and Dr Watson to get it set up and approved in these countries and negotiate with Amazon as an approved vendor of CBD and mushrooms,” he said.

BXN announced recently it hit a $1 million annualised revenue run rate in May 2023 for Dr Watson sales to Amazon in the UK, only 3 months after launch.

“Australia is due to go live in the coming months,” Watson said.

Bioxyne’s BLS imports THC flower into Australia

Meanwhile, BLS has announced it has now imported 100kg of 22% to 27% THC flower into Australia across five different genetics from South America and Europe.

In Australia, BLS holds licenses to import, export, wholesale Schedule 3, 4, and 8 controlled substances including medicinal cannabis and ketamine.

The company is awaiting its TGA Pharmaceutical GMP inspection scheduled for September 2023, allowing it to scale its existing production capabilities significantly.

It also holds licences to import medicinal cannabis, MDMA and Psilocybin into Australia, facilitating online patient consultations with doctors under the newly introduced authorised prescriber scheme and access to these alternative medicines.

This article was developed in collaboration with Bioxyne, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.